Lee Sun Jae, Yu Eunsil, Bae Young Kyung, Jang Kee-Taek, Kim Joon Mee, Bae Han-Ik, Hong Seung-Mo, Yoon Ghil Suk
Department of Pathology, Kyungpook National University School of Medicine, Daegu, Korea.
Korean J Pathol. 2012 Oct;46(5):415-22. doi: 10.4132/KoreanJPathol.2012.46.5.415. Epub 2012 Oct 25.
Small intestinal adenocarcinomas (SACs) are rare malignancies of the alimentary tract with uncertain carcinogenesis.
We investigated the expression of deleted in pancreatic cancer 4 (DPC4) in 188 cases of surgically resected SACs, using tissue microarray technology.
Twenty-four of the 188 tumors showed complete loss of Smad4/DPC4 expression in cytoplasm (score, 0; 12.8%). Eighty-four and 31 cases were moderately and strongly positive, respectively (score, 2 and 3; 44.7% and 16.5%, respectively) and 49 cases were focally or weakly stained (score, 1; 29.1%). Immunohistochemistry analysis showed that the expression of Smad4/DPC4 was related to an increased risk of lymphatic invasion but not to other clinicopathological features of the tumors (tumor location, differentiation, growth pattern, T stage, direct invasion, vascular invasion, and nodal metastasis). There was no significant association between Smad4/DPC4 expression and patient survival.
The present research is the first study to evaluate Smad4/DPC4 expression in a large sample of SACs with clinicopathologic correlation. Future studies should focus on the immunohistochemical and molecular characteristics of SACs to clarify their tumorigenesis.
小肠腺癌(SACs)是消化道罕见的恶性肿瘤,其致癌机制尚不清楚。
我们采用组织芯片技术,研究了188例手术切除的SACs中胰腺癌缺失4(DPC4)的表达情况。
188例肿瘤中有24例在细胞质中显示Smad4/DPC4表达完全缺失(评分,0;12.8%)。84例和31例分别为中度和强阳性(评分,2和3;分别为44.7%和16.5%),49例为局灶性或弱阳性(评分,1;29.1%)。免疫组化分析显示,Smad4/DPC4的表达与淋巴侵犯风险增加有关,但与肿瘤的其他临床病理特征(肿瘤位置、分化程度、生长方式、T分期、直接侵犯、血管侵犯和淋巴结转移)无关。Smad4/DPC4表达与患者生存率之间无显著相关性。
本研究是首次对大量SACs样本进行Smad4/DPC4表达及其临床病理相关性评估的研究。未来的研究应聚焦于SACs的免疫组化和分子特征,以阐明其肿瘤发生机制。